ClinicalTrials.gg
RecruitingNCT06201078PROSTAREUpdated Mar 13, 2025

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy

A Phase 2 interventional study of Stereotactic Body Radiotherapy in Local Recurrence of Malignant Tumor of Prostate and Radiotherapy, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 1 site in Poland. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2023, registered Dec 2023).
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Study summary

The goal of this clinical study is to evaluate the toxicity and efficacy of re-irradiation using focal stereotactic body radiotherapy (SBRT) in patients with local recurrence of prostate cancer after definitive or post-operative radiotherapy.

The main question is the tolerance of such treatment, concerning the incidence of Grade ≥ 2 and Grade ≥ 3 GU and GI toxicity. Also the efficacy of SBRT will be measured in terms of Biochemical Control with other secondary endpoints which include: Biochemical Response, Biochemical Failure-Free Survival, Metastases-Free Survival, Relapse-Free Survial, Local Control, Overall Survival and patients' reported tolerance measured with Quality of Life questionnaires (QoL C-30 and PR-25).

The evaluation of the tolerance and effectiveness of stereotactic radiotherapy (SBRT) will be performed in 3 subgroups: in patients with local recurrence after conventionally fractionated/moderately hypofractionated definitive radiotherapy (Group A) or ultrahypofractionated definitive SBRT (Group C) or after prostatectomy and post-operative radiotherapy (Group B).

The study group is planned to include 55 patients.

Read the detailed description

The diagnosis of local recurrence after radiotherapy in patients with prostate cancer is a serious clinical problem. Interventional salvage treatment in the previously irradiated area is difficult with safety issues of special concern. According to the MASTER meta-analysis the effectiveness of various local salvage methods turned out to be comparable in patients with local recurrence after definitive radiotherapy. Stereotactic radiotherapy (SBRT) had the best toxicity profile, so this non-invasive treatment may be a suitable alternative to other methods. A particular problem is local recurrences after post-prostatectomy radiotherapy. The data on SBRT in such setting are even more scarce than in the case of relapses after definitive radiotherapy. Still, they show a low percentage of serious adverse events of grade ≥3 and good treatment tolerance.

Considering the own experience with re-irradiation of patients with prostate cancer, it was decided that re-irradiation should be carried out in the form of focal SBRT. With the objective of enhancing the safety and quality of salvage re-irradiation, and a comprehensive evaluation of the efficacy of this treatment it was determined that it should be implemented as a prospective phase II study- PROSTARE (PROstate cancer STereotActic Reirradiation).

The evaluation of the tolerance and effectiveness of stereotactic radiotherapy (SBRT) will be performed in patients with local recurrence after conventionally fractionated/moderately hypofractionated definitive radiotherapy (Group A), ultrahypofractionated definitive SBRT (Group C), or after prostatectomy and postoperative radiotherapy (Group B).

The study will be conducted as a single-centre study. The evaluation of the safety and effectiveness of such treatment could help develop qualification criteria for repeated irradiation. As a consequence, this should allow for the implementation of this form of treatment into radiotherapy protocols and then, in a controlled and safe way, into clinical practice.

The total sample size will comprise 55 patients. The expected recruitment period is 6 years (10 patients per year).

Requirements for reirradiation with SBRT:

  1. Both PET-PSMA and MR of the prostate or prostate bed are required in patients with recurrence after definitive radiotherapy or surgery followed by radiotherapy
  2. Fiducial implantation is not routinely required
  3. Empty rectum and partially empty/partially filled bladder (improved reproducibility)* during treatment planning and during each fraction of stereotactic radiotherapy
  4. Treatment with a linear accelerator is preferred
  5. CBCT must be performed before each fraction of SBRT with verification for tumour location (GTV)**
  6. Focal radiotherapy, i.e., irradiation of only the visible tumour with an appropriate margin
  7. Hormonal treatment is not routinely recommended (according to the ESTRO ACROP consensus) - up to the decision of the attending physician

    • Principles of preparation with laxatives - Bisacodyl is advocated 4-5 hours before SBRT. If the diameter of the rectum on the CT for treatment planning exceeds 4 cm in diameter, the procedure should be repeated after appropriate preparation of the patient.

      • If stereotactic radiotherapy is conducted on the CyberKnife - KV imaging and Tracking verification are required; additionally an assessment of bladder filling in ultrasonography should be performed
02

Conditions studied

  • Local Recurrence of Malignant Tumor of Prostate
  • Radiotherapy

Keywords

  • local recurrence
  • prostate
  • radiotherapy
  • salvage
03

In context

Lead sponsor

Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Local recurrence of prostate cancer after definitive radiotherapy

    1. proven or/and
    2. Consistent MRI and PET-PSMA results and PSA growth dynamics
  2. Time since primary radiotherapy - at least 2 years
  3. Good performance status (ZUBROD 0-1)

    • If the results of the MRI and PET PSMA are inconsistent, and if there is no technical possibility of performing an MRI biopsy, the treatment is acceptable, but repeated imaging (PET or MRI) should be performed to assess the dynamics of the recurrence.

Exclusion criteria

Exclusion Criteria:

  1. Polymetastatic dissemination in distant or regional lymph nodes (N1, M1) or oligometastatic dissemination, but not eligible for local forms of directed therapy (MDT)
  2. Tumour volume (GTV) > 14 cc
  3. Poor tolerability of primary radiotherapy (≥G3 toxicity) or persistent late toxicity ≥G2 interfering with re-irradiation
  4. Severe dysuria before repeated SBRT (e.g., IPSS ≥19)
  5. Diseases of the distal part of the rectum or anal canal that may affect SBRT tolerance (e.g., anal fissure)
  6. Previous prostate brachytherapy
  7. Substantial risk for further urologic interventions (e.g., TURB/TURP)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Salvage SBRT for locally recurrent prostate cancer after radiotherapy

    SBRT: 5 x 6.75 Gy (every other day) to the total dose of 33.75 Gy

    Radiation: Stereotactic Body Radiotherapy

Interventions

  • RadiationStereotactic Body Radiotherapy

    Salvage SBRT will be performed in three subgroups of patients with local recurrence: Group A - after conventionally fractionated/moderately hypofractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT Target volumes: GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\* \*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm. Dose constrains: The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed: * Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%) * Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%) Dose-volume constrains: Rectum: • D30% \<15Gy Bladder: • D30% \< 15 Gy

06

What researchers measure

Primary outcomes

  1. Tolerance of salvage SBRT

    Assessment of early and late radiation toxicity: Grade ≥ 3 radiation-induced bladder/urethral (GU) and bowel/rectal (GI) adverse events toxicity or other, according to CTCAE criteria

    Time frame: 3 months post-SBRT, 2-years post-SBRT

Secondary outcomes

  1. Tolerance of salvage SBRT

    Rate of moderate or worse early and late radiation toxicity: Grade ≥ 2 radiation-induced bladder/urethral (GU) and bowel/rectal (GI) adverse events toxicity or other, according to CTCAE criteria

    Time frame: 3 months post-SBRT, every 6 months post SBRT up to 3-years post-SBRT

  2. Biochemical Control

    Biochemical Control will be defined as observations without biochemical recurrence defined as PSA concentration: a. \>2 ng/mL above the nadir (according to Phoenix) for groups A and C b. \>0.2 ng/ml (according to AUA) for group B

    Time frame: 3 months post-SBRT, 6 months post SBRT, every 6 months thereafter up to 5-years post-SBRT

  3. Biochemical Response

    Decrease in PSA level below baseline (pre-SBRT)

    Time frame: 3 months post-SBRT, 6 months post-SBRT, every 6 moths thereafter up to 5-years post-SBRT

  4. Biochemical Failure-Free Survival (BFS)

    Biochemical Failure Free Survival (BFS) is defined as the time interval between SBRT and biochemical, local, regional failure, distant metastasis or death irrespective of the cause

    Time frame: 3 months post-SBRT, 6 months post SBRT, every 6 months thereafter up to 5-years post-SBRT

  5. Metastases-Free Survival

    Metastases-Free Survival is the time interval between SBRT and occurrence of distant metastases or death irrespective of the cause

    Time frame: 1-year post SBRT, then annually up to 5-years post-SBRT

  6. Relapse-Free Survival

    Relapse-Free Survival is the time interval between SBRT and occurrence of clinical relapse: local recurrence, regional or distant metastases, start of hormonal therapy, or death irrespective of the cause

    Time frame: 1-year post SBRT, then annually up to 5-years post-SBRT

  7. Local Control

    Local Control is defined as the observations without local failure (within prostate or prostate bed): 1. in-field 2. out-field

    Time frame: 1-year post SBRT, then annually up to 5-years post-SBRT

  8. Overall Surival

    Overall Survival is the time interval between SBRT and patient death irrespective of the cause

    Time frame: 3 months post-SBRT, 6 months post-SBRT, every 6 moths thereafter up to 5-years post-SBRT

  9. Patients' reported Quality of Life

    Evaluation of EORTC QLQ-C30 and PR-25 questionnaires

    Time frame: 2-years post SBRT, 3-years post SBRT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 Sep;80(3):280-292. doi: 10.1016/j.eururo.2020.11.010. Epub 2020 Dec 11. PubMed 33309278 ↗
  • Miszczyk M, Kraszkiewicz M, Moll M, Kaminiow K, Sobel S, Dolla L, Wojcieszek P, Rajwa P, Yanagisawa T, Nowicka Z, Shariat SF, Goldner G, Miszczyk L, Majewski W. Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity. Cancers (Basel). 2023 Feb 13;15(4):1180. doi: 10.3390/cancers15041180. PubMed 36831523 ↗
  • Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM, Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T, Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treat Rev. 2021 Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. PubMed 33965893 ↗
  • Archer P, Marvaso G, Detti B, Colombo F, Francolini G, Vandendorpe B, Thananayagam MA, Baty M, De Crevoisier R, Alongi F, Nicosia L, Scher N, Toledano A, Di Muzio N, Fodor A, Zilli T, Franzese C, Scorsetti M, Shelan M, Triggiani L, Aymes E, Le Deley MC, Jereczek-Fossa BA, Pasquier D. Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study. Eur Urol Oncol. 2023 Jun;6(3):303-310. doi: 10.1016/j.euo.2023.03.005. Epub 2023 Apr 1. PubMed 37012102 ↗
  • Schroder C, Tang H, Windisch P, Zwahlen DR, Buchali A, Vu E, Bostel T, Sprave T, Zilli T, Murthy V, Forster R. Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review. Cancers (Basel). 2022 Jan 29;14(3):696. doi: 10.3390/cancers14030696. PubMed 35158961 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2029, 77 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2023
First posted
Jan 11, 2024
StartActual
Jul 31, 2023
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06201078
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Jul 31, 2023
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 13, 2025

Study contacts

Wojciech Majewski, MD, PhD
Contact
wojciech.majewski@gliwice.nio.gov.pl
+48322788001
Aleksandra Napieralska, MD, PhD
Contact
aleksandra.napieralska@gliwice.nio.gov.pl
+48322788001
Wojciech Majewski, MD, PhD
principal investigator · Maria Sklodowska Curie Memorial Research Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion